416 related articles for article (PubMed ID: 17240478)
1. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.
Fardet L; Dupuy A; Kerob D; Levy A; Allez M; Begon E; Bachelez H; Morel P; Lebbé C
J Am Acad Dermatol; 2007 Apr; 56(4):624-8. PubMed ID: 17240478
[TBL] [Abstract][Full Text] [Related]
2. Infliximab for the treatment of hidradenitis suppurativa.
Fernández-Vozmediano JM; Armario-Hita JC
Dermatology; 2007; 215(1):41-4. PubMed ID: 17587838
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa.
Mekkes JR; Bos JD
Br J Dermatol; 2008 Feb; 158(2):370-4. PubMed ID: 18047504
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.
Gener G; Canoui-Poitrine F; Revuz JE; Faye O; Poli F; Gabison G; Pouget F; Viallette C; Wolkenstein P; Bastuji-Garin S
Dermatology; 2009; 219(2):148-54. PubMed ID: 19590173
[TBL] [Abstract][Full Text] [Related]
5. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
van Rappard DC; Leenarts MF; Meijerink-van 't Oost L; Mekkes JR
J Dermatolog Treat; 2012 Aug; 23(4):284-9. PubMed ID: 21756155
[TBL] [Abstract][Full Text] [Related]
6. Hidradenitis suppurativa responding to treatment with infliximab.
Lasocki A; Sinclair R; Foley P; Saunders H
Australas J Dermatol; 2010 Aug; 51(3):186-90. PubMed ID: 20695857
[TBL] [Abstract][Full Text] [Related]
7. Etanercept: effective in the management of hidradenitis suppurativa.
Cusack C; Buckley C
Br J Dermatol; 2006 Apr; 154(4):726-9. PubMed ID: 16536817
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa.
Lesage C; Adnot-Desanlis L; Perceau G; Bonnet M; Palot JP; Bernard P; Reguiaï Z
Eur J Dermatol; 2012; 22(5):640-4. PubMed ID: 22759562
[TBL] [Abstract][Full Text] [Related]
9. [Hidradenitis suppurativa. Response to treatment with infliximab].
Pedraz J; Daudén E; Pérez-Gala S; Goiriz-Valdés R; Fernández-Peñas P; García-Diez A
Actas Dermosifiliogr; 2007 Jun; 98(5):325-31. PubMed ID: 17555675
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers.
Delage M; Samimi M; Atlan M; Machet L; Lorette G; Maruani A
Acta Derm Venereol; 2011 Mar; 91(2):169-71. PubMed ID: 21384087
[TBL] [Abstract][Full Text] [Related]
11. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa.
Giamarellos-Bourboulis EJ; Pelekanou E; Antonopoulou A; Petropoulou H; Baziaka F; Karagianni V; Stavrianeas N; Giamarellou H
Br J Dermatol; 2008 Mar; 158(3):567-72. PubMed ID: 18076705
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
[TBL] [Abstract][Full Text] [Related]
13. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
[TBL] [Abstract][Full Text] [Related]
14. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.
Gulliver WP; Jemec GB; Baker KA
J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):911-4. PubMed ID: 21605174
[TBL] [Abstract][Full Text] [Related]
15. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment.
Soria A; Canoui-Poitrine F; Wolkenstein P; Poli F; Gabison G; Pouget F; Viallette C; Revuz J
Dermatology; 2009; 218(2):134-5. PubMed ID: 19060466
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
[TBL] [Abstract][Full Text] [Related]
17. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa.
van der Zee HH; Boer J; Prens EP; Jemec GB
Dermatology; 2009; 219(2):143-7. PubMed ID: 19590174
[TBL] [Abstract][Full Text] [Related]
18. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial.
Grant A; Gonzalez T; Montgomery MO; Cardenas V; Kerdel FA
J Am Acad Dermatol; 2010 Feb; 62(2):205-17. PubMed ID: 20115947
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
DE Oliveira JP; Levy A; Morel P; Guibal F
J Dermatol; 2008 Sep; 35(9):575-80. PubMed ID: 18837702
[TBL] [Abstract][Full Text] [Related]
20. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
